Page 30 - TD-1-2

Tumor Discovery Prognostic biomarkers in pancreatic cancer

demonstrated the accuracy of the prognostic model. PAAD have not been fully elucidated. In the future, the accuracy of
patients were divided into a low-risk group and a high-risk this model will be verified with more experiments to explore
group according to the median prognostic risk level. It was the role of lncRNA and its interaction with m6A.
found that the high-risk group had poorer survival than
the low-risk group. The model validation results of clinical 5. Conclusion
grouping showed that the model we constructed was Understanding the mechanism of m6A-related lncRNA in
more suitable for patients who are 65 years old and below, the development of PAAD may provide new ideas for the
female patients, and PAAD patients with tumor stage I and prognosis and treatment of pancreatic cancer patients. Our
II. Multivariate Cox regression analysis showed that the study provides new clues and ways for survival prediction
m6A-related lncRNAs prognostic model was an own risk in PAAD patients and may help to elucidate the process
factor for survival. ROC analysis showed that the model and mechanism of regulation between m6A and lncRNA.
outperformed traditional clinical features in predicting
survival in PAAD patients. In addition, a nomogram was Acknowledgments
constructed showing the agreement between the 1-, 3-,
and 5-year prognostic model prediction rates for PAAD We would like acknowledge TCGA for the dataset we
patients. In terms of the accuracy of the prognostic model extracted.
based on m6A-related lncRNAs in predicting patient Funding
survival, the prediction model can provide a certain basis
for subsequent research to identify new biomarkers. No external funding was received for this work.
TMB is the total number of somatically encoded mutations Conflict of interest
associated with the emergence of neoantigens that trigger
antitumor immunity [23,24] . Studies have reported that patients The authors declare that the research was conducted in the
with low-risk endometrial cancer have higher TMB and are absence of any commercial or financial relationships that
more sensitive to chemotherapy than patients with high-risk could be construed as a potential conflicts of interest. The
scores . Here, we found that TMB in the low-risk group was authors declare that they have no conflicts of interest.
[25]
lower than that in the high-risk group and then performed a
survival analysis of TMB, finding that the low – TMB group Author contributions
had better survival than the high TMB group. Risk scores Conceptualization: Yiyang Chen, Xi Ou
were used for survival analysis and found that patients with Formal analysis: Yiyang Chen, Yiju Gong
low TMB and low-risk scores had better survival. However, Writing – original draft: Yiyang Chen, Wanbang Zhou
our prognostic model showed that there was no significant Writing – review & editing: Yiyang Chen, Yiju Gong
difference between high- and low-risk groups when receiving
immunotherapy in the analysis of immune escape and All authors contributed to the article and approved the
immunotherapy, which is probably due to limited samples. submitted version.
More samples can be used in future studies. The tumor Ethics approval and consent to participate
microenvironment can regulate the biological properties
of tumor cells such as chemotherapy resistance through Not applicable.
metabolism and other means. Six drugs with significantly
different estimated IC50s were screened out between the Consent for publication
high- and low-risk groups. The low-risk group was found Not applicable.
to be more sensitive to most potential drugs, the discovery
of which may provide new insights into the subsequent Availability of data
treatment of patients with PAAD ideas. Pathological The datasets presented, in this study, can be found in online
stage is a decisive factor for the diagnosis and prognosis of
PAAD . The current staging is not precise in providing repositories. The names of the repository/repositories and
[26]
reliable predictions and reflecting the heterogeneity of PAAD. accession number(s) can be found in the article.
Therefore, it is critical to explore new potential predictive References
markers and immunotherapeutic agents. The m6A-related
lncRNA prognostic model established in this paper provides 1. Yan Q, Ni C, Lin Y, et al., 2021, ELK1 enhances pancreatic
a new idea for predicting the survival of PAAD patients. cancer progression via LGMN and correlates with poor
However, there are some shortcomings and limitations in this prognosis. Front Mol Biosci, 8: 764900.
study, the biological mechanisms of m6A-related lncRNAs https://doi.org/10.3389/fmolb.2021.764900

Volume 1 Issue 2 (2022) 13 https://doi.org/10.36922/td.v1i2.165